Abstract 3426
Background
Benefit of CT beyond standard 1st-line (L1) gemcitabine plus cisplatin (GEMCIS) or oxaliplatin (GEMOX) in aBTC is unclear. Our aim was to identify and validate prognostic factors for L2OS in aBTC to guide patient selection for 2nd line (L2) CT.
Methods
All consecutive patients with aBTC receiving L2 CT after GEMCIS/GEMOX L1 between 2003-2016 in 28 French centers were included. The association of clinico-biological data with L2OS was investigated in univariate and multivariate Cox analyses. A simple score was derived from the multivariate model. The model and score were validated in 3 external cohorts with similar inclusion criteria (Italy, France, UK).
Results
The development cohort included 405 patients treated with L1 GEMOX (91%) or GEMCIS. 55% were men; median age was 64 years. 27% had prior surgical resection; 95% had metastatic disease. Performance status (PS) was 0/1/2 in 18%/52%/30%. Of the 251 patients with available CA19.9 at the beginning of L2, 35% had a CA19.9 ≥ 400 IU/L. Among 22 clinical parameters, 8 were associated with L2OS in univariate analysis. In multivariate analysis, 4 were independent prognostic factors: PS, reason for L1 stopping, prior surgery, peritoneal carcinomatosis (PC) (Table). Type of L2 CT regimen was not associated with L2OS. The clinical model had a C-index of 0.659, a good calibration and was validated in the 3 external cohorts (Table). Analysis of patients with complete data for the 4 clinical factors and CA19.9 (multiple imputations for missing data) showed that CA19.9 was independently associated with L2OS. A score was derived from this model.Table: 765P
Multivariate Cox Model for L2OS (HR, P-value)
| AGEO (N = 405) | ITALY (N = 288) | France (N = 70) | UK (N = 24) | |||||
|---|---|---|---|---|---|---|---|---|
| Prior surgery | ||||||||
| Yes No | 1 1.3 | 0.031 | 1 1.4 | 0.013 | 1 1.8 | 0.16 | 1 4.8 | 0.045 |
| Reason for L1 stopping | ||||||||
| Toxicity/ Other Progression | 1 1.5 | <0.001 | 1 1.8 | <0.001 | 1 3.0 | 0.0063 | 1 31.9 | <0.001 |
| PS | ||||||||
| 0 1 2 | 1 1.5 3.0 | <0.001 | 1 1.2 2.1 | 0.001 | 1 2.0 6.7 | <0.001 | 1 7.4 20.4 | 0.011 |
| PC | ||||||||
| No Yes | 1 1.3 | 0.018 | 1 1.4 | 0.019 | 1 1.0 | 1.0 | 1 15.3 | 0.001 |
Conclusions
We validated L2OS prognostic factors previously reported and identified PC as a new pejorative one in 800+ patients. Our model and score will be useful for guiding therapeutic decisions and stratifying randomization in future clinical trials.
Clinical trial identification
Legal entity responsible for the study
AGEO (Association des GastroEntérologues Oncologues) academic group.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
C. Neuzillet: Research funding (outside the study): Celgene; Clinical trial PI: AstraZeneca. A. Casadei Gardini: Consulting, Advisory role: Eisai; Speakers\' bureau: Bayer. B.J.-C. Rousseau: Advisory board: Bayer. M. Scartozzi: Consulting Advisory role, Speakers\' bureau: Bayer, Amgen, Merck, Sanofi; Research funding : Bayer, Msd, Bms, Sanofi. A. Lievre: Consulting, Advisory role: Merck, Amgen, Bayer, Ipsen, Shire; Speakers\' bureau: Merck, Roche, Amgen, Bayer, Ipsen, Novartis, BMS. All other authors have declared no conflicts of interest.
Resources from the same session
4784 - Tranilast inhibits TGF-beta-induced EMT and invasion/metastasis via the suppression of Smad4 in lung cancer cell lines.
Presenter: Koji Takahashi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
767 - Integrin beta-like 1 overexpression stimulates invasiveness of ovarian cancer cells in vitro
Presenter: Alexander Cortez
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
938 - MiR-449a suppresses endometrial cancer invasion and metastasis by targeting NDRG1
Presenter: Lihua Qiu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4866 - Cancer-associated fibroblasts-derived VEGFA mediates the migration of gastric cancer cells through VEGFR1
Presenter: xiaoxun Wang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4934 - Risk prediction of metastasis through study of circulating tumor cells
Presenter: Panagiotis Apostolou
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3289 - First step to metastasis: miRNAome abnormalities impair cell-cell adhesion and facilitate detachment of breast cancer cells
Presenter: Volodymyr Halytskiy
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4110 - Extracellular matrix of normal brain tissue is affected by temozolomide during anti-glioblastoma treatment
Presenter: Alexandra Tsidulko
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1526 - Study of the activation of TLR receptors in neurospheres from glioblastoma cells in vitro
Presenter: David Albert Bellver
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4862 - 5-Fluorouracil induced up-regulation of exosomal PD-L1 causing immunosuppression in gastric cancer patients
Presenter: Zhang Min
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
635 - Thrombocytosis and leukocytosis: are they negative prognostic factors in solid tumours?
Presenter: Filip Kohutek
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract